GET DAILY SIGNALSRxSight (RXST) Q3 2026: Revenue Drops 19% as Lens Volumes Face Competition
Key Takeaways
- RxSight reported third-quarter 2026 revenue of $24.6 million, down 19% from $30.3 million a year earlier and below the roughly $27.2 million consensus estimate.
- Adjusted earnings per share (EPS) came in at a loss of $0.21, narrower than the consensus estimate of a $0.29 loss, driven in part by tighter cost control.
- Light Adjustable Lens (LAL) procedure volume declined 11% year-over-year to 23,128 units, reflecting ongoing competitive pressures in the premium intraocular lens market.
- Gross margin compressed to 73.6% from 79.9% a year ago, weighed down by higher inventory reserves.
- The company ended the quarter with $254.7 million in cash and short-term investments, including a $60 million upfront payment from its Alcon collaboration.
Why These Results Matter for Investors
RxSight is a commercial-stage medical technology company focused on the Light Adjustable Lens (LAL), a premium cataract lens that lets physicians fine-tune a patient's vision after surgery using ultraviolet light delivered through the company's Light Delivery Device (LDD). Because the business is still scaling, investors pay close attention to procedure volumes and gross margin trajectory rather than bottom-line profitability alone. The third quarter arrived at a delicate moment: management had already withdrawn full-year 2026 guidance in the prior quarter following a CEO transition, while a new Alcon strategic collaboration and rising competitive activity in the premium intraocular lens (IOL) market reshaped the growth narrative. I also checked this using Tickeron’s AI Screener to see how RXST compares to others in the industry.
What the Numbers Showed
For the third quarter of fiscal 2026, RxSight reported total revenue of $24.6 million, a 19% decline from $30.3 million in the year-ago period and below the consensus estimate of roughly $27.2 million. LAL procedure revenue accounted for $22.8 million of the total, while LAL procedure volume fell 11% year-over-year to 23,128 units. Management attributed the softness primarily to ongoing competitive pressures.
On profitability, the company posted a Generally Accepted Accounting Principles (GAAP) net loss of $16.2 million, or $0.39 per basic and diluted share. After adjusting for $7.6 million in stock-based compensation, the non-GAAP net loss was $8.6 million, or $0.21 per share—narrower than the $0.29 adjusted loss Wall Street had expected. Gross margin slipped to 73.6% from 79.9% a year earlier, reflecting an increase in inventory reserves partially offset by a favorable product mix. Selling, general and administrative (SG&A) expenses were $27.4 million, essentially flat year-over-year, while research and development (R&D) spending held steady at $9.2 million.
How the Market Responded
The market's initial response to the report was negative, with shares trading lower in the after-hours session as the top-line miss outweighed the EPS beat. The revenue shortfall—driven by declining LAL procedure volumes—reinforced concerns that competitive trialing among rival presbyopia-correcting lenses is pressuring demand. Investor sentiment has been cautious for much of 2026, reflecting the withdrawal of full-year guidance, a leadership transition, and an ongoing securities class action. While the company's $254.7 million cash position, bolstered by the Alcon upfront payment, provides financial runway, the near-term reaction underscores that investors are focused on procedure-volume recovery and margin stability rather than cost discipline alone.
What to Watch Going Forward
Looking ahead, the central question is whether LAL procedure volumes can stabilize and return to growth. Competition in the premium IOL category remains intense, and investors will want evidence that RxSight's commercial realignment and customer engagement programs are translating into higher utilization across its installed base of Light Delivery Devices.
Gross margin will be another key watch item. The third-quarter decline was driven by inventory reserves, and management has previously flagged that higher-cost inventory manufactured in 2025 could flow through results. Whether margins normalize as production levels stabilize will help determine the company's path toward profitability.
The Alcon collaboration also deserves attention. While the upfront payment strengthened the balance sheet, investors will monitor how the partnership contributes to revenue and whether it accelerates international expansion in Asia and Europe. Finally, with full-year guidance withdrawn, any commentary from the new leadership team about a refreshed strategic direction or reinstated outlook will likely be a significant catalyst for the stock. From what I see, these elements will shape the near-term trajectory.
My Take on Using AI Tools for Research
When analyzing names like RXST, I often turn to Tickeron’s AI Screener to quickly filter comparable medical device stocks and spot patterns in procedure-related metrics or sector trends. It helps me cross-check fundamentals and technical signals without spending hours on manual reviews, giving a clearer picture of where RXST stands relative to peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RXST's RSI Indicator climbs out of oversold territory
The RSI Oscillator for RXST moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 45 similar instances when the indicator left oversold territory. In 37 of the 45 cases the stock moved higher. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RXST as a result. In 74 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for RXST just turned positive on October 07, 2026. Looking at past instances where RXST's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +4.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXST advanced for three days, in 234 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 62 cases where RXST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
RXST broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RXST entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.725) is normal, around the industry mean (4.170). P/E Ratio (-4.026) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.749) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. RXST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement